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ECTOPIC MINERALIZATION IN SKIN
DISEASES
Skin diseases characterized by aberrant
accumulation of mineral deposits
comprise a heterogeneous group of
disorders, often associated with inflam-
mation (Sprecher, 2010). Examples of
such conditions are systemic autoim-
mune disorders, for example, dermato-
myositis, lupus erythematosus, and
systemic sclerosis. Localized inflamma-
tory lesions, such as those in acne
and skin cancers, can also develop
localized foci of mineralization. The
mechanisms of ectopic mineralization
in these relatively common conditions
are largely unknown. However, clues
to the mineralization processes affect-
ing the skin have emerged from studies
on rare heritable single gene disorders
with profound mineralization of the
skin. The paradigm of such mineraliza-
tion disorders is pseudoxanthoma elas-
ticum (PXE), a multi-system disease
with protean manifestations in the skin,
the eyes, and the cardiovascular system
(Neldner, 1988). In fact, the significant
milestones of progress made in under-
standing this disorder serve as exam-
ples of the power of molecular genetics
towards identification of the candidate
genes and pathogenic mutations, with
translational implications (Uitto et al.,
2010, 2011).
PXE—THE PARADIGM OF ECTOPIC
MINERALIZATION DISORDERS
PXE was initially described as a clinical
syndrome with characteristic skin find-
ings, ocular involvement, and cardio-
vascular manifestations (Neldner,
1988). The cutaneous lesions, i.e.,
small yellowish papules, which tend
to coalesce into leathery and inelastic
skin, demonstrate accumulation of
pleiomorphic elastic structures in
mid-dermis, which by diagnostic
histopathologic examination reveals
progressive mineralization. Although
the cutaneous findings primarily pre-
sent a cosmetic problem and do not
interfere with the normal life activities,
they signify the risk for development of
ocular and vascular complications that
can be quite debilitating, with consid-
erable morbidity and occasional pre-
mature mortality. The skin findings are
associated with ocular involvement,
manifesting with angioid streaks and
progressive loss of visual acuity, occa-
sionally resulting in blindness. The
cardiovascular manifestations include
hypertension, intermittent claudication,
occasional bleeding from the gastro-
intestinal vessels, and early myocardial
infarcts, reflecting calcification of the
arterial blood vessels.
CANDIDATE GENES AND GENE DISCOVERY
As the histopathology of skin in PXE
reveals abnormal elastic structures, the
genes that participate in the synthesis
and assembly of the elastic fibers were
initially considered as a candidate
gene/protein system for mutations in
this disorder. This included the elastin
gene on chromosome 7q, as well as a
number of elastin-associated micro-
fibrillar proteins, such as fibrillins 1
and 2, fibulins 2, 3, and 4, and lysyl
oxidases. However, with cloning of the
corresponding genes, linkage analyses
systematically excluded these chromo-
somal regions as the sites of ‘‘the PXE
gene’’ (Christiano et al., 1992;
Raybould et al., 1994). The first mile-
stone of molecular genetics on PXE
consisted of a collaborative teamwork,
organized primarily by PXE Interna-
tional, the premiere patient advocacy
organization, which established link-
age of the PXE gene to the short-arm of
chromosome 16 (Le Saux et al., 1999;
Cai et al., 2000). The critical interval
initially consisted of B500 kb of
human genome that contained four
annotated genes, and examination of
the human genome database revealed
that none of these genes had an
obvious connection to extracellular
matrix of connective tissue in general
or the elastic fiber network in particu-
lar. Another milestone consisted of
systematic sequencing of these candi-
date genes, which resulted in identi-
fication of the ABCC6 gene as the one
harboring mutations in PXE (Bergen
et al., 2000; Le Saux et al., 2000;
Ringpfeil et al., 2000; Struk et al.,
2000). This gene encodes a trans-
membrane efflux transporter protein,
ABCC6, a member of the family of
multi-drug resistance proteins (MRP6).
The gene consists of 31 exons spanning
B75 kb of the human genome on
chromosomal region 16p13.1.
MUTATION SPECTRUM AND GENETIC
HETEROGENEITY
Following the initial identification of
ABCC6 as the PXE gene, more than
300 distinct mutations representing
over 1,000 mutant alleles have been
encountered in patients with PXE
from varied ancestral and ethnic
backgrounds (Chassaing et al., 2005;
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Miksch et al., 2005; Pfendner et al.,
2007; Li et al., 2009a). The types of
mutations include missense and non-
sense mutations, intronic mutations
causing missplicing, small deletions or
insertions within exons resulting in
frameshift of translation, as well as
large deletions spanning part or the
entire coding region of ABCC6, and
sometimes even including flanking
genes. Two recurrent mutations of high
frequency have been identified, one
of them being p.R1141X in exon 24,
which accounts for B30% of all
pathogenic PXE mutations. In addition,
a recurrent deletion of exons 23–29
(del23–29; pA999-S1403del) has been
found in at least one ABCC6 allele in
20% of US and 12% of European
patients. With the expansion of the
ABCC6 mutation database, these ge-
netic lesions can be used for confirma-
tion of the clinical diagnosis, carrier
detection, and presymptomatic identi-
fication of affected individuals. Further-
more, early identification of the disease
has aided in increased surveillance of
the clinical complications, allowing
prevention, and undoubtedly improv-
ing the quality of life of the affected
individuals.
Although it is clear that mutations in
the ABCC6 gene underlie most cases
with classic forms of PXE, defects in
additional genes have recently been
discovered to result in PXE-like cuta-
neous findings. A particularly intriguing
observation, with potential patho-
mechanistic implications for PXE, was
demonstration that patients with
vitamin K-dependent coagulation fac-
tor deficiency due to mutations in the
GGCX gene, can also have PXE-like
cutaneous findings (Vanakker et al.,
2007; Li et al., 2009b). In addition to
characteristic cutaneous lesions similar
to those seen in PXE, i.e., small yellow-
ish papules, these patients demonstrate
excessive folding and sagging of the
skin with loss of recoil. These patients
were initially described as having
combined clinical features of both
PXE and cutis laxa. However, the
cutaneous lesions in these patients
depict characteristic mineralization of
dermal elastic structures similar to PXE.
More recently, another gene, ENPP1,
which underlies generalized arterial
calcification of infancy, a severe miner-
alization disease affecting the cardio-
vascular system that often leads to early
demise of the affected individuals with-
in the first few years of life, has also
shown to be associated with PXE-like
cutaneous findings (Li et al., 2012;
Nitschke et al., 2012).
The GGCX gene encodes an en-
zyme responsible for g-glutamyl car-
boxylation of Gla-proteins, such as
vitamin K-dependent coagulation fac-
tors and matrix Gla-protein, the latter
being a powerful anti-mineralization
factor expressed in peripheral connec-
tive tissues. Most of these patients show
inactivating missense mutations in both
alleles of GGCX, clinically manifesting
with both PXE-like cutaneous findings
and bleeding tendency. In some cases,
the GGCX mutations were shown to be
heterozygous in combination with a
heterozygous ABCC6 mutation, mani-
festing with cutaneous findings consis-
tent with PXE but without coagulation
disorder, suggesting digenic inheri-
tance of PXE in this family (Li et al.,
2009c). These milestones attest to the
presence of an intricate mineralization/
anti-mineralization network in the skin
and indicate that mutations in different
genes involved in ectopic tissue miner-
alization can result in PXE-like pheno-
types.
MODEL SYSTEMS AND PATHOMECHANISMS
An early, somewhat puzzling observa-
tion on PXE was that the ABCC6 gene is
expressed primarily in the liver and to a
lesser extent in the proximal tubules
of kidneys, and only at very low level,
if at all, in tissues demonstrating
ectopic mineralization (Belinsky and
Kruh, 1999; Scheffer et al., 2002). The
pathomechanistic details of PXE remain
unclear, and in particular, the identity
of the molecules transported from liver
to the circulation by ABCC6 remains to
be disclosed. However, significant pro-
gress has been made in understanding
the molecular nature of PXE. The
critical milestone towards understand-
ing this disease was development of
transgenic animal models with features
of PXE (Gorgels et al., 2005; Klement
et al., 2005). Specifically, targeted
ablation of the mouse Abcc6 gene
results in a phenotype that recapitulates
features of human PXE, including late-
onset (5–6 weeks after birth), pro-
gressive mineralization of connective
tissues. The mineral deposits accumu-
lating in peripheral connective tissues
of these mice have been shown to
consist of calcium and phosphate
forming hydroxyapatite crystals, similar
to that in patients with PXE (Walker
et al., 1989; Kavukcuoglu et al., 2012).
This mouse model has served as a
platform to study the consequences of
Abcc6 mutations utilizing skin grafting
and parabiotic pairing model systems
(Jiang et al., 2009, 2010a). These
experiments have provided evidence
that PXE is a metabolic disorder in
which absence of ABCC6 transporter
activity in the liver results in deficiency
of circulating anti-mineralization fac-
tors, which in wild-type mice prevent
precipitation of calcium/phosphate
complexes under normal homeostatic
conditions (Figure 1). One such circu-
lating factor has been suggested to be
vitamin K or its derivatives, such as
reduced vitamin K–glutathione conju-
gate, which is required for activation of
the matrix Gla-protein by g-glutamyl
carboxylase, a vitamin K–dependent
enzyme (Borst et al., 2008). This hypo-
thesis has been tested in Abcc6/
mice by feeding them with excessive
amounts of vitamin K (Brampton et al.,
2011; Gorgels et al., 2011; Jiang et al.,
2011). The results indicated that vita-
min K supplementation did not prevent
ectopic mineralization in the Abcc6/
mouse model, suggesting that peri-
pheral tissue mineralization in PXE is
not a result of deficiency in vitamin K
concentration in tissues.
The nature of the substrate trans-
ported by ABCC6 in the liver has also
been examined by development of an
in vitro cell-based transporter system
(Ilias et al., 2002). In this system, insect
Sf9 cells are transfected with human
ABCC6 expression vector, and the
cells are then used to make inside-out
vesicles that can be used in transport
assays. This assay system has revealed
that ABCC6 can transport anionic small
molecular weight compounds, but spe-
cifically, ABCC6 does not transport
vitamin K–glutathione conjugate (Fu¨lo¨p
et al., 2011).
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TREATMENT PROSPECTS FOR PXE
Two lines of milestone studies have
suggested potential treatment modal-
ities for PXE, currently an intractable
disorder. One of those studies is
predicated on prevention of minerali-
zation that could be helpful in lessen-
ing the clinical manifestation of PXE
irrespective of the pathomechanisms.
Specifically, a set of experiments has
suggested that supplementation of
diet with magnesium will prevent the
deposition of mineral in connective
tissue (LaRusso et al., 2009; Gorgels
et al., 2010; Li and Uitto, 2010). Speci-
fically, experiments using the Abcc6/
animal model have shown that supple-
mentation of the diet with magnesium
up to 5-fold completely prevents the
development of ectopic mineralization
up to 6 months of age. Conversely, diet
that is low in magnesium and high
in phosphate has been shown to
accelerate the mineralization process
in PXE mice (LaRusso et al., 2008;
Li and Uitto, 2010; Jiang and Uitto,
2012). Thus, these studies examining
the precise role of different mineral
components in the diet, using the
preclinical animal models, have led to
development of clinical trials to test the
feasibility of this approach to treat
patients with PXE.
Another potential way of preventing
ectopic mineralization revolves around
the supplementation of anti-mineraliza-
tion factors to the circulation. One of
such molecules is fetuin-A, a powerful
anti-mineralization factor that is able to
prevent aberrant mineralization under
normal physiologic calcium and phos-
phate homeostatic conditions (Jahnen-
Dechent et al., 1997). The possibility of
using fetuin-A is strengthened by
demonstration that concentrations of
fetuin-A in serum of patients with
PXE as well as in Abcc6/ mice are
reduced (Hendig et al., 2006; Jiang
et al., 2007), and in fact, overexpres-
sion of fetuin-A in the liver of Abcc6/
mice has been shown to result in
lessening of the mineralization (Jiang
et al., 2010b). Additional strategies aim
at regeneration of liver by introduction
of allogeneic stem cells with capability
to differentiate into hepatocytes, which
could result in restoration of functional
ABCC6 transporter activity. An exten-
sion of this strategy would be liver
transplantation or a partial lobe repla-
cement as a means to restore the
ABCC6 activity.
An intriguing possibility is that
distinct mutations in the ABCC6
gene have different pathomechanistic
Figure 1. Conceptual illustration of the proposed metabolic hypothesis of PXE. Under physiologic conditions, the ABCC6 protein is expressed in high levels
in the liver, presumably transporting critical metabolites to the circulation (right panel). In the absence of ABCC6 transporter activity in the liver, changes
in the concentration of such substrate molecules in the circulation can take place, and the changes result in mineralization of a number of tissues, such as
the eye, the arterial blood vessels, the kidney, and the skin (middle panel). The presence of mineralization is detected in transgenic Abcc6/ mice that
recapitulate features of human PXE, by Alizarin red stain (left panel).
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consequences with respect to ABCC6
activity, which manifest as ectopic
mineralization. Although most of the
pathogenic lesions are nonsense muta-
tions resulting in reduced or absent
synthesis of the ABCC6 protein or
missense mutations that result in in-
activation of the transporter function,
certain mutations have been shown to
impair the intracellular trafficking of
transporter-competent ABCC6 proteins
(Ilias et al., 2002). Specifically, two
missense mutations, p.R1138Q and
p.R1314W, have been shown in in vitro
assays to retain significant transporter
activity, yet both mutant proteins dis-
play endoplasmic reticulum localization
in vivo. The cellular localization of
p.R1314W mutant was improved by
treatment with 4-phenylbutyrate, a che-
mical chaperone that facilitates traffick-
ing of misfolded proteins, thus
potentially rescuing its physiological
function (Le Saux et al., 2011). This
work demonstrates the feasibility of the
in vivo rescue of cellular maturation of
some ABCC6 mutants depending on the
specific mutation. Collectively, devel-
opment of molecular strategies can
provide new avenues for treatment and
eventual cure of PXE, a currently
intractable disease.
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